P R O B I O T H E R A P Y

BILLIONS OF GOOD BACTERIA FIGHTING FOR YOUR SKIN


CREATE A BACTERIAL REVOLUTION The natural alternative for antibiotics

> "Antibiotic resistance is one of the biggest threats to global health, food security, and developments today."

> > (WHO)

"Drug resistance deadlier than cancer by 2050"

(UK Government Study)




A UNIQUE AND PATENTED R&D SOLUTION

Live bacteria in water-based environments

11.0

SCIENTIFIC TRIAL

It is not magic ... it is, but scientifically proven



POST-MARKET FOLLOW UP STUDY

- Feedback received
 - 52 dermatologists (6.5% of Belgian total)
 - 199 patients

Patient population

- Average age (n=174): 22,72 [min. 10 max. 69]
- Gender: 34,7% male 65,3% female
- Severity: 46,6% mild 53,4% moderate
- Result
 - 165 patients (95%) showed improvement
 - No difference between dermato & patient score




A MICROBIOME PRODUCT RANGE For common skin conditions with marketing focus on acne



BEST OF BOTH WORLDS

As effective as a medicine AND as safe as a cosmetic



LAUNCH RESULTS

Belgian market, based on 4 months results



YUN TEAM

We are building a high performance organization



Tom Verlinden CEO

Kamato Executive Board Member

Qualiphar / Gifrer

Qualiphar / Gifrer Vice President



Ingmar Claes CSO





Tom Gybels CCO

SBS (Liberty Global) CCO

Omega Pharma/Perrigo Global Commercial VP

P&G Sales Director BNL Beauty Care




Jan-Frederik Mahieu CFO

Ideal Standard EU Finance Director, BU Fittings

> Ideal Standard EU Finance Director, CO

P&G WE Finance Manager, Supply Chain

2019 PIPELINEAnd the story will continue...



2018 YUN Probiotherapy

THE NEXT CHAPTER

YUN is looking for a strategic partner to bring the pipeline alive

2018 YUN Probiotherapy

P R O B I O T H E R A P Y

THANK YOU

For more information, please contact: CEO Tom Verlinden tom.verlinden@yun-probiotherapy.com +32 477 46 24 53